dc.creatorOrellana Urzúa, Sofía
dc.creatorRojas, Ignacio
dc.creatorLíbano, Lucas
dc.creatorRodrigo Salinas, Ramón
dc.date.accessioned2021-03-28T21:18:12Z
dc.date.available2021-03-28T21:18:12Z
dc.date.created2021-03-28T21:18:12Z
dc.date.issued2020
dc.identifierCurrent Pharmaceutical Design Volumen: 26 Número: 34 Páginas: 4246-4260 (2020)
dc.identifier10.2174/1381612826666200708133912
dc.identifierhttps://repositorio.uchile.cl/handle/2250/178830
dc.description.abstractStroke is the second leading cause of mortality and the major cause of adult physical disability worldwide. The currently available treatment to recanalize the blood flow in acute ischemic stroke is intravenous administration of tissue plasminogen activator (t-PA) and endovascular treatment. Nevertheless, those treatments have the disadvantage that reperfusion leads to a highly harmful reactive oxygen species (ROS) production, generating oxidative stress (OS), which is responsible for most of the ischemia-reperfusion injury and thus causing brain tissue damage. In addition, OS can lead brain cells to apoptosis, autophagy and necrosis. The aims of this review are to provide an updated overview of the role of OS in brain IRI, providing some bases for therapeutic interventions based on counteracting the OS-related mechanism of injury and thus suggesting novel possible strategies in the prevention of IRI after stroke.
dc.languageen
dc.publisherBentham Science, U Arab Emirates
dc.sourceCurrent Pharmaceutical Design
dc.subjectIschemia-reperfusion
dc.subjectOxidative stress
dc.subjectReactive oxygen species
dc.subjectIschemic stroke
dc.subjectHaemorrhagic stroke
dc.subjectAntioxidant
dc.titlePathophysiology of Ischemic Stroke: Role of Oxidative Stress
dc.typeArtículo de revista


Este ítem pertenece a la siguiente institución